Tumor Biology

, Volume 36, Issue 5, pp 3285–3291 | Cite as

MicroPET imaging of tumor angiogenesis and monitoring on antiangiogenic therapy with an 18F labeled RGD-based probe in SKOV-3 xenograft-bearing mice

  • Guangjie Yang
  • Pei Nie
  • Yu Kong
  • Hukui Sun
  • Guihua Hou
  • Jiankui Han
Research Article


So far, there is no satisfactory imaging modality to monitor antiangiogenesis therapy of ovarian cancer noninvasively. The aim of this study was to evaluate the effectiveness and sensibility of an 18F labeled Arg-Gly-Asp (RGD) peptide in imaging and monitoring antiangiogenic responds in SKOV-3 xenograft-bearing mice. 18F-FB-NH-PEG4-E[PEG4-c(RGDfK)]2 (denoted as 18F-RGD2) was synthesized and employed in this study. Mice bearing ovarian cancer SKOV-3 tumors were used for biodistribution and microPET imaging studies compared with 18F-FDG imaging. Animals were treated with low-dose paclitaxel and the effect of paclitaxel therapy on 18F-RGD2 accumulation was investigated. Microvascular density (MVD) of SKOV-3 tumors was detected to assess the reliability of 18F-RGD2 in antiangiogenesis monitoring. Biodistribution studies for 18F-RGD2 revealed favorable in vivo pharmacokinetic properties, with significant levels of receptor-specific tumor uptake determined via blocking studies. MicroPET imaging results demonstrated high contrast visualization of SKOV-3 tumors. And tumor to background ratio (T/NT) of 18F-RGD2 uptake was significantly higher than that of 18F-FDG. Studies on antiangiogenic therapy demonstrated percentage of injected dose per gram of tissue (%ID/g) tumor uptake of 18F-RGD2 which was obviously decreased in the treatment group than the control group, especially at 60 min (by 31.31 ± 7.18 %, P = 0.009) and 120 min (by 38.92 ± 8.31 %, P < 0.001) after injection of 18F-RGD2. MVD measurement of SKOV-3 tumors confirmed the finding of the biodistribution studies in monitoring antiangiogenesis therapy. 18F-RGD2, with favorable biodistribution properties and specific affinity, is a promising tracer for tumor imaging and monitoring antiangiogenesis therapy in ovarian cancer SKOV-3 xenograft-bearing mice.


Ovarian cancer Monitoring antiangiogenic therapy Target imaging RGD peptide Integrin imaging 



This work was supported by grants from the National Natural Science Foundation of China No. 81071172. The authors would like to thank Nanjing PET-Tracer Co., Ltd (Nanjing, Jiangsu, China) for the assistance with radiosynthesis of 18F-RGD2.


  1. 1.
    Ferlay J, Soerjomataram I, Ervik M, Forman D, Bray F. GLOBOCAN, GLOBOCAN. Cancer incidence and mortality worldwide; 2012.
  2. 2.
    Syrios J, Banerjee S, Kaye SB. Advanced epithelial ovarian cancer: from standard chemotherapy to promising molecular pathway targets—where are we now? Anticancer Res. 2014;34:2069–77.PubMedGoogle Scholar
  3. 3.
    Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N. SEER Cancer Statistics Review, 1975–2010, National Cancer Institute. Bethesda, MD, 2014;
  4. 4.
    PPerren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase III trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.CrossRefGoogle Scholar
  5. 5.
    Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.CrossRefPubMedGoogle Scholar
  6. 6.
    Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007;6:2012–21.CrossRefPubMedGoogle Scholar
  7. 7.
    Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039–45.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Chauhan VP, Stylianopoulos T, Martin JD, Popović Z, Chen O, Kamoun WS, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol. 2012;7:383–8.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Beer AJ, Kessler H, Wester HJ, Schwaiger M. PET imaging of integrin αvβ3 expression. Theranostics. 2011;1:48–57.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Haubner R, Wester HJ. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des. 2004;10:1439–55.CrossRefPubMedGoogle Scholar
  11. 11.
    Mittra ES, Goris ML, Iagaru AH, Kardan A, Burton L, Berganos R, et al. Pilot pharmacokinetic and dosimetric studies of 18F-FPPRGD2: a PET radiopharmaceutical agent for imaging αvβ3 integrin levels. Radiology. 2011;260:182–91.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157–64.CrossRefPubMedGoogle Scholar
  13. 13.
    Moncelet D, Bouchaud V, Mellet P, Ribot E, Miraux S, Franconi JM, et al. Cellular density effect on RGD ligand internalization in glioblastoma for MRI application. PLoS One. 2012;8:e82777.CrossRefGoogle Scholar
  14. 14.
    Metz S, Ganter C, Lorenzen S, van Marwick S, Herrmann K, Lordick F, et al. Phenotyping of tumor biology in patients by multimodality multiparametric imaging: relationship of microcirculation, alphavbeta3 expression, and glucose metabolism. J Nucl Med. 2010;51:1691–8.CrossRefPubMedGoogle Scholar
  15. 15.
    HHaubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med. 2005;2:e70.CrossRefGoogle Scholar
  16. 16.
    Lau DH, Xue L, Young LJ, Burke PA, Cheung AT. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm. 1999;14:31–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ, Sukhatme VP. Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. Int J Cancer. 2005;113:490–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Pasquier E, Carré M, Pourroy B, Camoin L, Rebaï O, Briand C, et al. Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther. 2004;3:1301–10.PubMedGoogle Scholar
  19. 19.
    Yang G, Sun H, Kong Y, Hou G, Han J. Diversity of RGD radiotracers in monitoring antiangiogenesis of flavopiridol and paclitaxel in ovarian cancer xenograft-bearing mice. Nucl Med Biol. 2014;41:856–62.CrossRefPubMedGoogle Scholar
  20. 20.
    Cai W, Olafsen T, Zhang X, Cao Q, Gambhir SS, Williams LE, et al. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med. 2007;48:304–10.CrossRefPubMedGoogle Scholar
  21. 21.
    Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett. 2012;320:130–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med. 2008;49 Suppl 2:113–28.CrossRefGoogle Scholar
  24. 24.
    Gaertner FC, Kessler H, Wester HJ, Schwaiger M, Beer AJ. RGD radiotracers for imaging and therapy. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 1:126–38.CrossRefGoogle Scholar
  25. 25.
    Jung KH, Lee KH, Paik JY, Ko BH, Bae JS, Lee BC, et al. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. J Nucl Med. 2006;47:2000–7.PubMedGoogle Scholar
  26. 26.
    Dumont RA, Hildebrandt I, Su H, Haubner R, Reischl G, Czernin JG, et al. Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. Cancer Res. 2009;69:3173–9.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Jin ZH, Furukawa T, Claron M, Boturyn D, Coll JL, Fukumura T, et al. Positron emission tomography imaging of tumor angiogenesis and monitoring of antiangiogenic efficacy using the novel tetrameric peptide probe 64Cu-cyclam-RAFT-c(−RGDfK-)4. Angiogenesis. 2012;15:569–80.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Aten E. Efficacy study of [F-18]RGD-K5 positron emission tomography (PET) as a tool to monitor response to an anti-angiogenic drug (K5-101).; 2009.Google Scholar
  29. 29.
    Winick J. A proof-of-concept study to assess the ability of [18F]AH-111585 PET imaging to detect tumours and angiogenesis.; 2007.Google Scholar
  30. 30.
    Kyung Moon W. PET-MR for prediction and monitoring of response to neoadjuvant chemotherapy in breast cancer.; 2010.Google Scholar
  31. 31.
    Gleeson F. RGD-PET-CT in cancer angiogenesis.; 2011.Google Scholar
  32. 32.
    Gambhir S. 18F FPPRGD2 positron emission tomography/computed tomography in predicting early response in patients with cancer receiving anti-angiogenesis therapy.; 2013.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of Nuclear Medicine, Qilu HospitalShandong UniversityJinanChina
  2. 2.Department of Radiologythe Affiliated Hospital of Qingdao UniversityQingdaoChina
  3. 3.Key Laboratory for Experimental Teratology of the Ministry of Education and Institute of Experimental Nuclear Medicine, School of MedicineShandong UniversityJinanChina

Personalised recommendations